YARNO WENDY L 4

What Happened
Wendy L. Yarno, a director of Tarsus Pharmaceuticals (TARS), had 2,954 Restricted Stock Units (RSUs vest) converted into 2,954 shares on 2026-06-12. The Form 4 shows an acquisition of 2,954 shares pursuant to settlement of vested RSUs and a simultaneous disposition of 2,954 shares at $0.00. The report lists the acquisition price as N/A and the disposition proceeds as $0, indicating no cash sale in the open market.

Key Details

• Transaction date: 2026-06-12; Form 4 filed 2026-06-16 (filed within required period).
• Acquired: 2,954 shares via settlement of vested RSUs (reported as conversion of derivative).
• Disposed: 2,954 shares at $0.00 (same number as acquired).
• Reported values: acquisition price N/A; disposition proceeds $0.
• Footnotes: RSUs were granted on June 12, 2025 for non-employee director service and vested in full on the one-year anniversary (per filing).
• Net change in beneficial ownership from these entries: 0 shares (2,954 acquired and 2,954 disposed).
• Shares owned after transaction: not specified in the provided excerpt.

Context

• This is a routine settlement of director RSUs, not an open-market purchase or sale. The paired acquisition and $0 disposition typically reflect shares issued on vesting with an equal number withheld or surrendered to satisfy tax withholding obligations (common practice), rather than a market sale.
• Such award settlements are compensation-related and do not necessarily signal insider confidence or a change in investment view.